These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15059702)

  • 21. Assessing the impact of protocol design changes on clinical trial performance.
    Getz KA; Wenger J; Campo RA; Seguine ES; Kaitin KI
    Am J Ther; 2008; 15(5):450-7. PubMed ID: 18806521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of patients who dropout from a glaucoma clinic.
    Ashaye AO; Adeoye AO
    J Glaucoma; 2008; 17(3):227-32. PubMed ID: 18414110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications.
    Noecker RJ; Walt JG
    Am J Ophthalmol; 2006 Jan; 141(1 Suppl):S15-21. PubMed ID: 16389056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bias reduction with an adjustment for participants' intent to dropout of a randomized controlled clinical trial.
    Leon AC; Demirtas H; Hedeker D
    Clin Trials; 2007; 4(5):540-7. PubMed ID: 17942469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience.
    Rahman MQ; Montgomery DM; Lazaridou MN
    Br J Ophthalmol; 2009 Dec; 93(12):1572-5. PubMed ID: 19628493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study.
    Brandt JD; Beiser JA; Gordon MO; Kass MA;
    Am J Ophthalmol; 2004 Nov; 138(5):717-22. PubMed ID: 15531304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study.
    Caprioli J; Coleman AL
    Ophthalmology; 2008 Jul; 115(7):1123-1129.e3. PubMed ID: 18082889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial.
    Matsuyama Y
    Stat Med; 2010 Sep; 29(20):2107-16. PubMed ID: 20552682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials.
    Brittain E; Lin D
    Stat Med; 2005 Jan; 24(1):1-10. PubMed ID: 15532089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of the efficacy of glaucoma medications in regulatory trials: Phase I-III to post-marketing studies.
    Stewart WC; Jenkins JN
    Eye (Lond); 2008 Aug; 22(8):985-8. PubMed ID: 17585308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
    Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
    Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accounting for restart rates in evaluating persistence with ocular hypotensives.
    Schwartz GF; Platt R; Reardon G; Mychaskiw MA
    Ophthalmology; 2007 Apr; 114(4):648-52. PubMed ID: 17398318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
    Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
    Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interpretation of the glaucoma "landmark studies".
    Wishart PK
    Br J Ophthalmol; 2009 May; 93(5):561-2. PubMed ID: 19395626
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication.
    Magacho L; Reis R; Shetty RK; Santos LC; Avila MP
    Ophthalmology; 2006 Mar; 113(3):442-5. PubMed ID: 16458964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials.
    van der Valk R; Webers CA; Schouten JS; Zeegers MP; Hendrikse F; Prins MH
    Ophthalmology; 2005 Jul; 112(7):1177-85. PubMed ID: 15921747
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a Bayesian network to predict the nighttime intraocular pressure peak from daytime measurements.
    Nordmann JP; Berdeaux G
    Clin Ther; 2007 Aug; 29(8):1751-60; discussion 1750. PubMed ID: 17919556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.